{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:22:43Z","timestamp":1778199763694,"version":"3.51.4"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To analyze the clinical and volumetric responses to different corticosteroid administration methods for IgG4-related ophthalmic disease (IgG4-ROD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The medical records of patients with bilateral lacrimal gland (LG) enlargement diagnosed with IgG4-ROD through unilateral LG biopsy between January 2011 and January 2022 were retrospectively reviewed. Clinical signs and the non-biopsied LG volume across three administration routes were compared: oral prednisolone (Pd), intravenous (IV) methylprednisolone (methylPd), and local triamcinolone (TA) injection. Radiological relapse was defined as the first instance of failure to satisfy the radiological response criteria, i.e., a post-treatment volume of &lt;1.0\u2009cm\n                      <jats:sup>3<\/jats:sup>\n                      or a post-treatment to pre-treatment volume ratio of &lt;35%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 28 patients, eight, ten, and ten received oral Pd, IV methylPd, and local TA injection, respectively. No significant differences were observed between the groups in terms of the baseline characteristics. Ophthalmic adverse effects were not observed in any patient. Kaplan\u2013Meier survival analysis revealed that the 2-year radiological relapse-free survival in the IV methylPd group (80.0%) was higher than that in the oral Pd group (37.5%, p\u2009=\u20090.036) but comparable with that in the local TA group (100.0%, p\u2009=\u20090.886). The median post-treatment to pre-treatment volume ratio in the IV methylPd group (35.4%) was significantly lower than that in the oral Pd group (75.0%, p\u2009=\u20090.042) but comparable with that in the local TA injection group (38.5%, p\u2009=\u20090.321) one year after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with oral Pd, IV methylPd yielded better and more sustained radiological responses in patients with LG-involving IgG4-ROD. Local TA injection was also an effective alternative treatment option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0332392","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:29:01Z","timestamp":1762194541000},"page":"e0332392","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of volumetric responses to different corticosteroid administration methods in IgG4-related ophthalmic disease"],"prefix":"10.1371","volume":"20","author":[{"given":"Min Kyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Jung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-7222","authenticated-orcid":true,"given":"Ho-Seok","family":"Sa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"6","key":"pone.0332392.ref001","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMra1104650","article-title":"IgG4-related disease","volume":"366","author":"JH Stone","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0332392.ref002","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/bjophthalmol-2017-310584","article-title":"Risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease","volume":"102","author":"J Park","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"pone.0332392.ref003","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00417-019-04327-w","article-title":"Clinicopathologic features of biopsied lacrimal gland masses in 95 Korean patients","volume":"257","author":"C Ahn","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"pone.0332392.ref004","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/ICU.0000000000000204","article-title":"Management of orbital IgG4-related disease","volume":"26","author":"LRD Glass","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"pone.0332392.ref005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10384-014-0353-1","article-title":"Ocular adnexal IgG4-related disease: clinical features, outcome, and factors associated with response to systemic steroids","volume":"59","author":"W-K Yu","year":"2015","journal-title":"Jpn J Ophthalmol"},{"issue":"4","key":"pone.0332392.ref006","article-title":"Efficacy and safety of intravenous glucocorticoid therapy for IgG4-related ophthalmic disease","volume":"18","author":"MK Yang","year":"2023","journal-title":"PLoS One"},{"issue":"5","key":"pone.0332392.ref007","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/bjophthalmol-2015-307164","article-title":"Intraorbital corticosteroid injection for the treatment of IgG4-related ophthalmic disease","volume":"100","author":"NH Andrew","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"pone.0332392.ref008","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10384-024-01072-4","article-title":"The 2023 revised diagnostic criteria for IgG4-related ophthalmic disease","volume":"68","author":"M Takahira","year":"2024","journal-title":"Jpn J Ophthalmol"},{"issue":"4","key":"pone.0332392.ref009","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/09273948.2021.1887282","article-title":"New onset of unilateral orbital myositis following mild COVID-19 infection","volume":"29","author":"MS Mangan","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"pone.0332392.ref010","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/09273948.2022.2093757","article-title":"Orbital inflammatory pseudotumor following mRNA COVID-19 vaccination","volume":"31","author":"A Yucel Gencoglu","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"pone.0332392.ref011","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/IOP.0b013e318293750c","article-title":"Local steroid injection for management of different types of acute idiopathic orbital inflammation: an 8-year study","volume":"29","author":"A El Nasser A Mohammad","year":"2013","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"1","key":"pone.0332392.ref012","doi-asserted-by":"crossref","first-page":"69","DOI":"10.18502\/jovr.v15i1.5948","article-title":"Intraorbital steroid injection for active thyroid ophthalmopathy","volume":"15","author":"A Bagheri","year":"2020","journal-title":"J Ophthalmic Vis Res"},{"issue":"2","key":"pone.0332392.ref013","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00417-016-3538-0","article-title":"Quantitative analysis of orbital soft tissues on computed tomography to assess the activity of thyroid-associated orbitopathy","volume":"255","author":"JS Byun","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"pone.0332392.ref014","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.23543","article-title":"An international multispecialty validation study of the IgG4-related disease responder index","volume":"70","author":"ZS Wallace","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"pone.0332392.ref015","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"MN Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0332392.ref016","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12886-021-02210-z","article-title":"Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients","volume":"21","author":"L Gan","year":"2021","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"pone.0332392.ref017","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.neurad.2021.01.006","article-title":"Imaging of IgG4-related disease in the head and neck: a systematic review, case series, and pathophysiology update","volume":"48","author":"F Behzadi","year":"2021","journal-title":"J Neuroradiol"},{"issue":"1","key":"pone.0332392.ref018","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10792-024-03287-3","article-title":"Comparison of lacrimal gland dimensions and volume in unilateral Ahmed glaucoma valve versus trabeculectomy","volume":"44","author":"HH Gobeka","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"6","key":"pone.0332392.ref019","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MNM.0000000000001566","article-title":"18F-fluorodeoxyglucose PET and PET\/computed tomography for the evaluation of immunoglobulin G4-related disease: a systematic review","volume":"43","author":"F Dondi","year":"2022","journal-title":"Nucl Med Commun"},{"issue":"1","key":"pone.0332392.ref020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13550-020-00743-w","article-title":"Disease activity and response to therapy monitored by [18F]FDG PET\/CT using volume-based indices in IgG4-related disease","volume":"10","author":"K Mitamura","year":"2020","journal-title":"EJNMMI Res"},{"issue":"3","key":"pone.0332392.ref021","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/rpd\/ncw382","article-title":"Estimation of the cumulative exposure frequency and cumulative effective dose of diagnostic medical radiation in the korean population from 2002 to 2010","volume":"176","author":"J-W Gil","year":"2017","journal-title":"Radiat Prot Dosimetry"},{"issue":"3","key":"pone.0332392.ref022","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2214\/AJR.12.9652","article-title":"The risk of cataract associated with repeated head and neck CT studies: a nationwide population-based study","volume":"201","author":"M-K Yuan","year":"2013","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"pone.0332392.ref023","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijom.2023.02.001","article-title":"Cumulative exposure and lifetime cancer risk from diagnostic radiation in patients undergoing orthognathic surgery: a cross-sectional analysis","volume":"52","author":"J Ver Berne","year":"2023","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"9","key":"pone.0332392.ref024","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1513\/pats.200808-079QC","article-title":"Radiation dose issues in longitudinal studies involving computed tomography","volume":"5","author":"JR Mayo","year":"2008","journal-title":"Proc Am Thorac Soc"},{"issue":"11","key":"pone.0332392.ref025","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/bjophthalmol-2017-311519","article-title":"Clinicoserological factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease","volume":"102","author":"JW Hong","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"pone.0332392.ref026","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1080\/14397595.2021.1878623","article-title":"Involvement of two or more sets of lacrimal glands and\/or major salivary glands is related to greater systemic disease activity due to multi-organ involvement in IgG4-related dacryoadenitis\/sialadenitis","volume":"31","author":"Y Takahashi","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"1","key":"pone.0332392.ref027","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13075-021-02489-9","article-title":"Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China","volume":"23","author":"Z Zhao","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"pone.0332392.ref028","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/apm.12845","article-title":"IgG4-related disease: review of the histopathologic features, differential diagnosis, and therapeutic approach","volume":"126","author":"JR Bledsoe","year":"2018","journal-title":"APMIS"},{"issue":"1","key":"pone.0332392.ref029","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13075-015-0698-y","article-title":"Clinicopathological characteristics of immunoglobulin G4-related sialadenitis","volume":"17","author":"W Li","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"pone.0332392.ref030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3341\/kjo.2016.30.5.319","article-title":"The change of lacrimal gland volume in korean patients with thyroid-associated ophthalmopathy","volume":"30","author":"H-D Huh","year":"2016","journal-title":"Korean J Ophthalmol"},{"issue":"10","key":"pone.0332392.ref031","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3341\/jkos.2014.55.10.1413","article-title":"Calculated brain CT angiography volumes of lacrimal glands in normal Korean orbits","volume":"55","author":"SH An","year":"2014","journal-title":"J Korean Ophthalmol Soc"},{"issue":"7","key":"pone.0332392.ref032","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International working group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"A Younes","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"pone.0332392.ref033","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/iovs.62.1.15","article-title":"Differential tissue metabolic signatures in IgG4-related ophthalmic disease and orbital mucosa-associated lymphoid tissue lymphoma","volume":"62","author":"H Shimizu","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"pone.0332392.ref034","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2215\/CJN.12331213","article-title":"Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study","volume":"9","author":"M Shinzawa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"pone.0332392.ref035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00915049","article-title":"Corticosteroid effects on circulating lymphocyte subset levels in normal humans","volume":"4","author":"B Zweiman","year":"1984","journal-title":"J Clin Immunol"},{"issue":"6","key":"pone.0332392.ref036","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaci.2003.09.028","article-title":"High-dose intravenous glucocorticoid therapy abrogates circulating dendritic cells","volume":"112","author":"T Suda","year":"2003","journal-title":"J Allergy Clin Immunol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:29:06Z","timestamp":1762194546000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332392"}},"subtitle":[],"editor":[{"given":"Francesca","family":"Torrini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332392","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}